Jeffrey A. Meckler net worth and biography

Jeffrey Meckler Biography and Net Worth

Jeffrey Meckler currently serves as our Chief Executive Officer, bringing more than 30 years of financial and healthcare leadership experience to the company. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.

What is Jeffrey A. Meckler's net worth?

The estimated net worth of Jeffrey A. Meckler is at least $121,681.90 as of November 18th, 2022. Mr. Meckler owns 65,774 shares of Indaptus Therapeutics stock worth more than $121,682 as of April 1st. This net worth evaluation does not reflect any other assets that Mr. Meckler may own. Learn More about Jeffrey A. Meckler's net worth.

How do I contact Jeffrey A. Meckler?

The corporate mailing address for Mr. Meckler and other Indaptus Therapeutics executives is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. Indaptus Therapeutics can also be reached via phone at (646) 374-8050 and via email at [email protected] Learn More on Jeffrey A. Meckler's contact information.

Has Jeffrey A. Meckler been buying or selling shares of Indaptus Therapeutics?

Jeffrey A. Meckler has not been actively trading shares of Indaptus Therapeutics during the last ninety days. Most recently, on Monday, November 21st, Jeffrey A. Meckler bought 9,600 shares of Indaptus Therapeutics stock. The stock was acquired at an average cost of $1.90 per share, with a total value of $18,240.00. Following the completion of the transaction, the chief executive officer now directly owns 75,374 shares of the company's stock, valued at $143,210.60. Learn More on Jeffrey A. Meckler's trading history.

Who are Indaptus Therapeutics' active insiders?

Indaptus Therapeutics' insider roster includes Jeffrey Meckler (CEO), and Michael Newman (Director). Learn More on Indaptus Therapeutics' active insiders.

Are insiders buying or selling shares of Indaptus Therapeutics?

In the last year, Indaptus Therapeutics insiders bought shares 7 times. They purchased a total of 41,185 shares worth more than $101,931.41. The most recent insider tranaction occured on December, 1st when insider Boyan Vesselinov Litchev bought 500 shares worth more than $935.00. Insiders at Indaptus Therapeutics own 36.0% of the company. Learn More about insider trades at Indaptus Therapeutics.

Information on this page was last updated on 12/1/2022.

Jeffrey A. Meckler Insider Trading History at Indaptus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2022Buy9,600$1.90$18,240.0075,374View SEC Filing Icon  
11/18/2022Buy400$1.76$704.0065,774View SEC Filing Icon  
9/8/2022Buy10,308$2.80$28,862.4065,374View SEC Filing Icon  
6/6/2022Buy19,727$2.63$51,882.0145,374View SEC Filing Icon  
11/18/2021Buy11,187$5.82$65,108.34View SEC Filing Icon  
See Full Table

Jeffrey A. Meckler Buying and Selling Activity at Indaptus Therapeutics

This chart shows Jeffrey A Meckler's buying and selling at Indaptus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Indaptus Therapeutics Company Overview

Indaptus Therapeutics logo
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Read More

Today's Range

Now: $1.85
Low: $1.79
High: $1.88

50 Day Range

MA: $1.71
Low: $1.52
High: $1.90

2 Week Range

Now: $1.85
Low: $1.25
High: $4.25


6,691 shs

Average Volume

9,497 shs

Market Capitalization

$15.54 million

P/E Ratio


Dividend Yield